{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:11:32Z","timestamp":1778645492974,"version":"3.51.4"},"reference-count":14,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["101095426"],"award-info":[{"award-number":["101095426"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.mayocp.2025.07.017","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T08:17:45Z","timestamp":1756714665000},"page":"1465-1467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Acute Myeloperoxidase Inhibition: The Search for HFpEF Therapies Continues"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7781-2897","authenticated-orcid":false,"given":"Navin","family":"Suthahar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.mayocp.2025.07.017_bib1","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC Scientific Statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.mayocp.2025.07.017_bib2","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1161\/CIRCHEARTFAILURE.109.930701","article-title":"Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction","volume":"3","author":"Borlaug","year":"2010","journal-title":"Circ Heart Fail"},{"issue":"4","key":"10.1016\/j.mayocp.2025.07.017_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.mayocp.2025.07.017_bib4","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jchf.2023.04.009","article-title":"Myeloperoxidase in heart failure with preserved ejection fraction: a target against inflammation?","volume":"11","author":"de Boer","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"7","key":"10.1016\/j.mayocp.2025.07.017_bib5","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/ATVBAHA.119.312725","article-title":"Inhibition of MPO (myeloperoxidase) attenuates endothelial dysfunction in mouse models of vascular inflammation and atherosclerosis","volume":"39","author":"Cheng","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.mayocp.2025.07.017_bib6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/cvr\/cvab077","article-title":"Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes","volume":"118","author":"Ramachandra","year":"2022","journal-title":"Cardiovasc Res"},{"issue":"9","key":"10.1016\/j.mayocp.2025.07.017_bib7","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.mayocp.2025.02.022","article-title":"Acute effects of myeloperoxidase inhibition on exercise hemodynamics in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"100","author":"Popovic","year":"2025","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.mayocp.2025.07.017_bib8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cardfail.2023.04.003","article-title":"Myeloperoxidase inhibition in heart failure with preserved or mildly reduced ejection fraction: SATELLITE trial results","volume":"30","author":"Lam","year":"2024","journal-title":"J Card Fail"},{"issue":"9","key":"10.1016\/j.mayocp.2025.07.017_bib9","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1002\/ejhf.2977","article-title":"Rationale and design of ENDEAVOR: a sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction","volume":"25","author":"Lund","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.mayocp.2025.07.017_bib10","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrm2256","article-title":"ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis","volume":"8","author":"D\u2019Autr\u00e9aux","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.mayocp.2025.07.017_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55263-y","article-title":"Pharmacological myeloperoxidase (MPO) inhibition in an obese\/hypertensive mouse model attenuates obesity and liver damage, but not cardiac remodeling","volume":"9","author":"Piek","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.mayocp.2025.07.017_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1164\/rccm.201103-0468OC","article-title":"Late intervention with a myeloperoxidase inhibitor stops progression of experimental chronic obstructive pulmonary disease","volume":"185","author":"Churg","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.mayocp.2025.07.017_bib13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.tibs.2015.05.001","article-title":"Peroxiredoxins: guardians against oxidative stress and modulators of peroxide signaling","volume":"40","author":"Perkins","year":"2015","journal-title":"Trends Biochem Sci"},{"issue":"5","key":"10.1016\/j.mayocp.2025.07.017_bib14","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/ejhf.3653","article-title":"Peroxiredoxin-4, a marker of systemic oxidative stress, is associated with incident heart failure","volume":"27","author":"Suthahar","year":"2025","journal-title":"Eur J Heart Fail"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619625004057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619625004057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:36:13Z","timestamp":1778643373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619625004057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0025619625004057"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2025.07.017","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Myeloperoxidase Inhibition: The Search for HFpEF Therapies Continues","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2025.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2025.02.022","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}